Hopefully a Breakthrough (not yet clinical): CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy

[Maxone73]

Hopefully I won't be banned completely...meanwhile...let's hope this thing works because it would be quite powerful!

The new T cell engager, CLSP-1025, represents a major advance in cancer immunotherapy, targeting the common p53^R175H mutation found in multiple solid tumors. This innovative therapy is designed to precisely bind to the p53 mutant peptide, activating the immune system to attack cancer cells while sparing healthy ones. By focusing on this mutation, CLSP-1025 could benefit a wide range of patients with hard-to-treat cancers like lung, colorectal, and prostate. With promising preclinical results, CLSP-1025 may soon enter clinical trials, potentially transforming the treatment landscape for solid tumors by delivering targeted and effective immunotherapy.

prostatewarriors.com/2024/1...

[KocoPr]

excellent for so many patients and probably the most important gene to fix.